Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in...
96 insider sale filings on record · latest filing 2026-10-02.
No open-market insider purchases (SEC Form 4 code P) on record for MAZE.